Press

Mynd Life Sciences

Jan 12, 2022

MYND Life Sciences Announces Collaborative Research Agreement with University of British Columbia

MYND’s Second CRA focuses on Novel Therapies for Neurological Diseases of the Brain VANCOUVER, BC, Jan. 12, 2022 /CNW/ – MYND Life...

Mynd Life Sciences

Dec 15, 2021

MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application

VANCOUVER, BC, Dec. 15, 2021 /CNW/ – MYND Life Sciences Inc. (“MYND” or the “Company“) (CSE: MYND) (OTC: MYNDF) is pleased to announce it...

Mynd Life Sciences

Nov 30, 2021

MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

R&D project on psilocybin’s benefits in treating diseases of the brain VANCOUVER, BC, Nov. 30, 2021 /CNW/ – MYND Life Sciences...

Mynd Life Sciences

Nov 30, 2021

MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

R&D project on psilocybin’s benefits in treating diseases of the brain VANCOUVER, BC, Nov. 30, 2021 /CNW/ – MYND Life Sciences Inc. ...

MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test

Mynd Life Sciences

Nov 22, 2021

MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test

MYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis...

MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease

Mynd Life Sciences

Nov 16, 2021

MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease

The Company will be initiating a clinical validation study on the use of its proprietary biomarker testing in Alzheimer’s Disease...

MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist

Mynd Life Sciences

Nov 9, 2021

MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist

Focused on generating data through proprietary biomarkers and diagnostic testing of inflammation VANCOUVER, BC, Nov. 9, 2021 /CNW/ – MYND...

Mynd Life Sciences

Oct 28, 2021

MYND Life Sciences Announces Appointment of New Director

VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ – MYND Life Sciences Inc. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) announces the...

Mynd Life Sciences

Oct 27, 2021

MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer&

Acquisition will strengthen MYND’s psilocybin-assisted medicinal and diagnostics capabilities, adding novel psychedelics for the...

MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Mil

Mynd Life Sciences

Oct 13, 2021

MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Mil

Evaluating the efficacy of psilocybin-assisted psychotherapy in treatment resistant depression VANCOUVER, BC, Oct. 13, 2021 /CNW/ – MYND...

Mynd Life Sciences

Oct 12, 2021

MYND Life Sciences Inc. to Present at Psychedelics Virtual Investor Conference on October 13

VANCOUVER, BC, Oct. 11, 2021 /PRNewswire/ — MYND Life Sciences Inc. (CSE:MYND)(OTC:MYNDF), based in Vancouver BC, focused on novel...

Mynd Life Sciences

Oct 7, 2021

MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary – M

MYND Diagnostics was formed to commercialize proprietary biomarker diagnostic tests for patients suffering from MDD, TRD and other...

Mynd Life Sciences

Sep 29, 2021

MYND Life Sciences Inc. Announces RSU Grant

VANCOUVER, BC, Sept. 29, 2021 /CNW/ – MYND Life Sciences Inc. (“MYND” or the “Company“), has granted an aggregate of 234,192 restricted...

Mynd Life Sciences

Sep 9, 2021

MYND Life Sciences Announces Closing of Fully Subscribed $3 Million Convertible Debenture Unit Offer

VANCOUVER, BC, Sept. 9, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND” or the “Company“) is pleased to announce,...

Mynd Life Sciences

Aug 26, 2021

MYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering

VANCOUVER, BC, Aug. 26, 2021 /PRNewswire/ – MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND” or the “Company“), is pleased to...

Mynd Life Sciences

Aug 11, 2021

MYND Life Sciences Announces DTC Eligibility

VANCOUVER, BC, Aug. 11, 2021 /PRNewswire/ – MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND”) is a drug research and development...

Mynd Life Sciences

Jul 7, 2021

MYND Life Sciences Provides Corporate Update

VANCOUVER, BC, July 7, 2021 /PRNewswire/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND”) is a drug research and development company...

Mynd Life Sciences

Jul 4, 2021

This Canadian psychedelic drug company is working on a vaccine for depression

“Diagnosing, preventing and treating diseases of the central nervous system is at the core of our focused corporate strategy.”...

Mynd Life Sciences

Jun 23, 2021

MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related fo

VANCOUVER, BC, June 23, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND“) a drug research and development company focused on...

Mynd Life Sciences

Jun 17, 2021

MYND Life Sciences Announces LOI with Eyam Vaccines and Immunotherapeutics

VANCOUVER, BC, June 17, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND“) a drug research and development company focused on...

MENU

DIAGNOSTICS
INVESTING
SCIENCE

CONTACT
NEWS

MENU

DIAGNOSTICS INVESTING SCIENCE

CONTACT NEWS

DIAGNOSTICS
INVESTING
SCIENCE

CONTACT
NEWS